Literature DB >> 28778232

Idiopathic Hypersomnia.

Lynn Marie Trotti1.   

Abstract

Idiopathic hypersomnia (IH) is a chronic neurologic disorder of daytime sleepiness, accompanied by long sleep times, unrefreshing sleep, difficulty in awakening, cognitive dysfunction, and autonomic symptoms. The cause is unknown; a genetic predisposition is suggested. Autonomic, inflammatory, or immune dysfunction has been proposed. Diagnosis involves a clinical history and objective testing. There are no approved treatments for IH, but modafinil is typically considered first-line. A substantial fraction of patients with IH are refractory or intolerant to standard treatments, and different treatment strategies using novel therapeutics are necessary. Even with current treatment options, quality of life and safety may remain impaired.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Excessive daytime sleepiness; Idiopathic hypersomnia; Multiple sleep latency test; Narcolepsy; Sleep drunkenness

Mesh:

Substances:

Year:  2017        PMID: 28778232      PMCID: PMC5558858          DOI: 10.1016/j.jsmc.2017.03.009

Source DB:  PubMed          Journal:  Sleep Med Clin        ISSN: 1556-407X


  70 in total

1.  Different sleep onset criteria at the multiple sleep latency test (MSLT): an additional marker to differentiate central nervous system (CNS) hypersomnias.

Authors:  Fabio Pizza; Stefano Vandi; Stefania Detto; Francesca Poli; Christian Franceschini; Pasquale Montagna; Giuseppe Plazzi
Journal:  J Sleep Res       Date:  2011-03       Impact factor: 3.981

2.  Effects of pitolisant, a histamine H3 inverse agonist, in drug-resistant idiopathic and symptomatic hypersomnia: a chart review.

Authors:  Smaranda Leu-Semenescu; Nandy Nittur; Jean-Louis Golmard; Isabelle Arnulf
Journal:  Sleep Med       Date:  2014-03-18       Impact factor: 3.492

3.  Daytime alertness in Parkinson's disease: potentially dose-dependent, divergent effects by drug class.

Authors:  Donald L Bliwise; Lynn Marie Trotti; Anthony G Wilson; Sophia A Greer; Cathy Wood-Siverio; Jorge J Juncos; Stewart A Factor; Alan Freeman; David B Rye
Journal:  Mov Disord       Date:  2012-07-02       Impact factor: 10.338

4.  Modafinil improves real driving performance in patients with hypersomnia: a randomized double-blind placebo-controlled crossover clinical trial.

Authors:  Pierre Philip; Cyril Chaufton; Jacques Taillard; Aurore Capelli; Olivier Coste; Damien Léger; Nicholas Moore; Patricia Sagaspe
Journal:  Sleep       Date:  2014-03-01       Impact factor: 5.849

5.  Flumazenil for the Treatment of Refractory Hypersomnolence: Clinical Experience with 153 Patients.

Authors:  Lynn Marie Trotti; Prabhjyot Saini; Catherine Koola; Vincent LaBarbera; Donald L Bliwise; David B Rye
Journal:  J Clin Sleep Med       Date:  2016-10-15       Impact factor: 4.062

6.  The characteristics of sleep in patients with manifest bipolar disorder, subjects at high risk of developing the disease and healthy controls.

Authors:  Philipp S Ritter; Carolin Marx; Natalia Lewtschenko; Steffi Pfeiffer; Karolina Leopold; Michael Bauer; Andrea Pfennig
Journal:  J Neural Transm (Vienna)       Date:  2012-08-18       Impact factor: 3.575

7.  Polysomnographic study of nocturnal sleep in idiopathic hypersomnia without long sleep time.

Authors:  Fabio Pizza; Raffaele Ferri; Francesca Poli; Stefano Vandi; Filomena I I Cosentino; Giuseppe Plazzi
Journal:  J Sleep Res       Date:  2012-10-15       Impact factor: 3.981

Review 8.  Sleep circuitry and the hypnotic mechanism of GABAA drugs.

Authors:  Jun Lu; Mary Ann Greco
Journal:  J Clin Sleep Med       Date:  2006-04-15       Impact factor: 4.062

9.  Idiopathic hypersomnia with and without long sleep time: a controlled series of 75 patients.

Authors:  Cyrille Vernet; Isabelle Arnulf
Journal:  Sleep       Date:  2009-06       Impact factor: 5.849

10.  Improvement in daytime sleepiness with clarithromycin in patients with GABA-related hypersomnia: Clinical experience.

Authors:  Lynn Marie Trotti; Prabhjyot Saini; Amanda A Freeman; Donald L Bliwise; Paul S García; Andrew Jenkins; David B Rye
Journal:  J Psychopharmacol       Date:  2013-12-03       Impact factor: 4.153

View more
  7 in total

1.  Effects of Pharmacotherapy Treatment on Patient-Reported Outcomes in a Narcolepsy and Idiopathic Hypersomnia Cohort.

Authors:  Maeve Pascoe; James Bena; Nancy Foldvary-Schaefer
Journal:  J Clin Sleep Med       Date:  2019-10-30       Impact factor: 4.062

2.  Frequency and severity of autonomic symptoms in idiopathic hypersomnia.

Authors:  Mitchell G Miglis; Logan Schneider; Paul Kim; Joseph Cheung; Lynn Marie Trotti
Journal:  J Clin Sleep Med       Date:  2020-02-10       Impact factor: 4.062

3.  Optimizing Actigraphic Estimation of Sleep Duration in Suspected Idiopathic Hypersomnia.

Authors:  Jesse D Cook; Sahand C Eftekari; Lydia A Leavitt; Michael L Prairie; David T Plante
Journal:  J Clin Sleep Med       Date:  2019-04-15       Impact factor: 4.062

4.  Idiopathic Hypersomnia-A Dynamic Simulation Model.

Authors:  Marek Susta; Karel Šonka; Gustav Bizik; Svojmil Petranek; Sona Nevsimalova
Journal:  Front Neurol       Date:  2022-06-10       Impact factor: 4.086

5.  Diagnosing narcolepsy in the active duty military population.

Authors:  Bernadette Villarreal; Tyler Powell; Matthew S Brock; Shana Hansen
Journal:  Sleep Breath       Date:  2021-02-25       Impact factor: 2.816

Review 6.  Narcolepsy type 1: what have we learned from genetics?

Authors:  Hanna M Ollila
Journal:  Sleep       Date:  2020-11-12       Impact factor: 5.849

7.  Parthenogenetic mosaicism: generation via second polar body retention and unmasking of a likely causative PER2 variant for hypersomnia.

Authors:  Yohei Masunaga; Masayo Kagami; Fumiko Kato; Takeshi Usui; Takako Yonemoto; Kazuo Mishima; Maki Fukami; Kazushi Aoto; Hirotomo Saitsu; Tsutomu Ogata
Journal:  Clin Epigenetics       Date:  2021-04-07       Impact factor: 6.551

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.